Celldex Halts Trading Due to Volatility, Drops 21% After 52-Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Celldex Therapeutics experienced a significant decline, dropping 21% due to heightened market volatility following the release of 52-week results from its Phase 2 study of Barzolvolimab in the treatment of chronic spontaneous urticaria. The company’s stock was halted as investors reacted to the findings, underscoring the sensitivity of the market to clinical trial outcomes. The Phase 2 results, which are crucial for determining the drug’s efficacy and potential for future development, have sparked discussions among analysts and investors regarding the implications for the company’s future.